Tirzepatide
GIP/GLP-1 dual receptor agonist analog
A dual GIP and GLP-1 receptor agonist analog (39 amino acids, fatty-diacid-modified for extended half-life), studied in metabolic research as a next-generation incretin-pathway compound relative to single-agonist predecessors like semaglutide.
What researchers are studying Tirzepatide for.
Dual Incretin-Receptor Agonism
Glucose-Homeostasis Research
Body-Composition Research
39-amino-acid, fatty-diacid-modified GIP/GLP-1 dual analog — full sequence via certificate of analysis
Concentration and unit math, worked out.
Worked example for a 10mg vial reconstituted with 3mL of bacteriostatic water, drawn on a U-100 insulin syringe. Use the calculator below for any other vial size or water volume.
| UNITS DRAWN | VOLUME | DELIVERS |
|---|---|---|
| 5 units | 0.05 mL | 167 mcg |
| 10 units | 0.10 mL | 333 mcg |
| 20 units | 0.20 mL | 667 mcg |
| 30 units | 0.30 mL | 1000 mcg |
| 50 units | 0.50 mL | 1667 mcg |
Run your own numbers.
Pre-filled with a 30-day starting point — one vial, dosed once daily for 30 days. Adjust any field to match your own protocol.
RESULTS
Educational reference tool only — not medical advice. Reconstitution and dosing decisions for any research protocol should be reviewed with a qualified professional. Figures assume uniform mixing and standard syringe calibration; always verify against your own protocol.